Transcatheter Arterial Chemotherapy with Miriplatin for Hepatocellular Carcinoma Patients with Chronic Renal Failure: Report of Three Cases

Norihiro Imai, Kenji Ikeda, Yuya Seko, Yusuke Kawamura, Hitomi Sezaki, Tetsuya Hosaka, Norio Akuta, Masahiro Kobayashi, Satoshi Yaitoh, Fumitaka Suzuki, Yoshiyuki Suzuki, Yasuji Arase, and Hiromitsu Kumada

Department of Hepatology, Toranomon Hospital, Tokyo, Japan

Miriplatin is a novel lipophilic platinum complex that was developed to treat hepatocellular carcinoma (HCC). Although HCC patients frequently have coexisting chronic renal failure, little prospective data are available regarding the clinical toxicity of chemotherapeutic agents used to treat HCC patients with chronic renal failure. In a phase II study, the plasma concentration of total platinum in patients who received miriplatin was very low, and no severe renal toxicity caused by miriplatin injection was reported. Here, we present three cases of HCC with stage 4 chronic renal failure who received transcatheter arterial chemotherapy with miriplatin. All cases were male, ages 72, 84, and 83 years, and had serum creatinine levels of 2.3, 1.6, and 1.9 mg/dL, respectively. Their estimated glomerular filtration rates were 21.9, 20.3, and 22.2 mL/min, respectively. All cases were treated for unresectable HCC with transcatheter arterial chemotherapy with miriplatin. No serious adverse events were observed, and serum creatinine levels did not elevate, even in the patient who experienced renal failure caused by cisplatin administration. These results might suggest that transcatheter arterial chemotherapy with miriplatin can be safely used in HCC patients with chronic renal failure. (Gut Liver 2013;7:246-251)

Key Words: Miriplatin; Chronic renal failure; Hepatocellular carcinoma

INTRODUCTION

Hepatocellular carcinoma (HCC) is one of the most common malignant diseases worldwide. Since curative therapies, including resection, liver transplantation, and percutaneous ablation (percutaneous ethanol injection and radiofrequency ablation [RFA]) are applicable in only 30% to 40% of HCC patients, transcatheter arterial chemoembolization (TACE) has been recognized as an effective palliative treatment option for patients with advanced HCC. HCC patients frequently have coexisting cirrhosis, which is a predisposing factor for the development of renal dysfunction due to intravascular volume depletion, inadequate renal vasoconstriction, and hyperaldosteronism.

Little prospective data are available regarding the clinical toxicity of chemotherapeutic agents used to treat HCC patients with chronic renal failure. Although cisplatin is an effective anticancer drug that is widely used for the treatment of many malignancies, including HCC, it is associated with significant nephrotoxicity, particularly in patients with chronic renal failure. Miriplatin is a novel cisplatin derivative containing platinum with a high affinity for the iodized ethyl ester of fatty acids of poppyseed oil (Lipiodol Ultra-fluide; Laboratoire Guerbet, Aulnay-Sous-Bois, France) that is used in TACE. Clinical trials have demonstrated that miriplatin is effective in the treatment of HCC.

In a Phase II HCC study, the plasma concentration of total platinum in patients receiving miriplatin was very low, and no severe renal toxicity caused by miriplatin injection was reported. Here we present three cases of HCC with stage 4 chronic renal failure who received transcatheter arterial chemotherapy with miriplatin.

CASE REPORTS

1. Case 1

A 72-year-old man with HCC, liver cirrhosis, and diabetic nephropathy had undergone RFA four times and TACE three times over 5 years. As shown in Fig. 1, a computed tomography (CT) scan of the liver revealed multiple HCCs (tumor size, 15 to 34 mm; tumor number, three; stage, T2N0M0). The serum creat-
nine level was 2.3 mg/dL, and the estimated glomerular filtration rate (GFR) was 21.9 mL/min (Table 1).21

The patient was hydrated through a peripheral line. The femoral artery was catheterized under local anesthesia, and catheter was inserted superselectively into the hepatic artery that supplied the target tumor, for injection of the miriplatin/lipiodol suspension and 1 mm gelatin particles (1 mm-Gelpart; Nippon Kayaku, Tokyo, Japan). Miriplatin/lipiodol suspension was administrated slowly under careful fluoroscopic guidance. The dose of miriplatin/lipiodol was determined according to tumor size and the degree of liver dysfunction. The patient received TACE with miriplatin (miriplatin 50 mg, lipiodol 2.5 mL, and 1 mm-Gelpart were injected from both the right and left hepatic arteries). Therapy was well tolerated, and the patient’s weight and serum creatinine level remained stable after treatment (Fig. 2). Major side effects included grade 1 fever, elevated blood glucose, and grade 1 nausea, which all resolved within 1 week (the National Cancer Institute’s Common Terminology Criteria for Adverse Events [CTCAE] version 4.0). Treatment efficacy was assessed 1 month after treatment. Partial response (modified response evaluation criteria in solid tumors, mRECIST) was achieved in all target lesions.22

The patient was received two times TACE with miriplatin at intervals of 4 months after the first administration (second and third dosage of miriplatin were 120 mg and dosage of lipiodol were 6 mL). The patient’s weight and serum creatinine level still remained stable after repeat injection of miriplatin (serum creatinine level was 2.2 mg/dL after third TACE with miriplatin). Stable disease (mRECIST) was achieved in all target lesions after third TACE with miriplatin.

2. Case 2

An 84-year-old man with HCC, liver cirrhosis, and chronic renal failure had undergone RFA three times and TACE six times over 10 years. As shown in Fig. 3, a CT scan of the liver showed multiple HCCs (tumor size, 12 to 55 mm; tumor number, six; stage, T3N0M0). The serum creatinine level was 1.6 mg/dL, and the estimated GFR was 20.3 mL/min (Table 1).

The patient was hydrated through a peripheral line. The femoral artery was catheterized under local anesthesia, and catheter was inserted superselectively into the hepatic artery that supplied the target tumor, for injection of the miriplatin/lipiodol suspension. Miriplatin/lipiodol suspension was administrated slowly under careful fluoroscopic guidance. The dose of miriplatin/lipiodol was determined according to tumor size and the degree of liver dysfunction.

The patient received transcatheter arterial chemotherapy with miriplatin (miriplatin 50 mg and lipiodol 2.5 mL were injected from both the right and left hepatic arteries). Therapy was well tolerated, and the patient’s weight and serum creatinine level remained stable after treatment (Fig. 2). The major side effect of treatment was grade 1 fever, which resolved within 1 week (CTCAE version 4.0). Treatment efficacy was assessed 2 months after therapy. Stable disease (mRECIST) was achieved in all target lesions.

3. Case 3

An 83-year-old man with HCC, liver cirrhosis, hypertension,
and renal failure that had been caused by cisplatin administration had undergone TACE nine times over 4 years. As shown in Fig. 4, a magnetic resonance imaging scan of the liver revealed multiple HCCs (tumor size, 5 to 39 mm; tumor number, 40; stage, T2N0M0). The patient’s serum creatinine level was 1.9 mg/dL, and the estimated GFR was 22.2 mL/min (Table 1).

The patient was hydrated through a peripheral line. The femoral artery was catheterized under local anesthesia, and catheter was inserted superselectively into the hepatic artery that supplied the target tumor, for injection of the miriplatin/lipiodol suspension and 1 mm-Gelpart. Miriplatin/lipiodol suspension was administrated slowly under careful fluoroscopic guidance. The dose of miriplatin/lipiodol was determined according to tumor size and the degree of liver dysfunction.

The patient received TACE with miriplatin (miriplatin 30 mg, lipiodol 1.5 mL, and 1 mm-Gelpart were injected from the right and left hepatic arteries, and miriplatin 10 mg and lipiodol 0.5 mL were injected from the right inferior phrenic artery). Therapy was well tolerated, and the patient’s weight and serum creatinine level remained stable after treatment (Fig. 2). Major side effects included grade 1 fever and grade 1 nausea, both of which resolved within 1 week (CTCAE version 4.0). Treatment efficacy was assessed 3 months after therapy. Stable disease (mRECIST) was achieved in all target lesions.

**DISCUSSION**

Various anticancer drugs, such as doxorubicin hydrochloride, epirubicin hydrochloride, mytomycin C, cisplatin, and necarzinostatin, have been used at TACE agents for the treatment of HCC. However, the most effective and least toxic TACE protocol for HCC has yet to be identified.

Miriplatin is a novel lipophilic cisplatin derivative that can be suspended in lipiodol and used for transcatheter arterial che-

---

**Table 1. Patient Characteristics**

| Characteristic                              | Case 1 | Case 2 | Case 3 |
|--------------------------------------------|--------|--------|--------|
| Age                                        | 72     | 84     | 83     |
| Gender                                     | Male   | Male   | Male   |
| Height, cm                                 | 159    | 160    | 162    |
| Weight, kg                                 | 58     | 47     | 57     |
| Serum creatinine, mg/dL*                   | 2.3    | 1.6    | 1.9    |
| Estimated GFR1, mL/min†                    | 21.9   | 20.3   | 22.2   |
| Estimated GFR2, mL/min‡                    | 22.8   | 32.5   | 27.0   |
| Etiology                                   | HCV    | HCV    | HBV    |
| Child-Pugh score                           | A (6)  | A (5)  | A (5)  |
| ICG-R15, %                                 | 16     | 13     | 4      |
| Underlying disease that caused renal failure| Diabetic nephropathy | Chronic glomerulonephritis | Cisplatin induced renal failure |
| Tumor no.                                  | 3      | 6      | 40     |
| Maximum tumor size, mm                     | 34     | 55     | 39     |
| Cancer stage (TNM)                         | II (T2N0M0) | III (T3N0M0) | II (T2N0M0) |
| Dosage of miriplatin, mg                   | 100    | 100    | 70     |
| Dosage of lipiodol, mL                     | 5      | 5      | 3.5    |
| Use of gelatin sponge particles            | Yes    | No     | Yes    |
| Contrast medium, mL                        | Iomeprol 60 | Iomeprol 50 | Iomeprol 190 |
| Use of hydration therapy after miriplatin infusion | Yes    | Yes    | Yes    |

GFR, glomerular filtration rate; HCV, hepatitis C virus; HBV, hepatitis B virus; ICG-R15, indocyanine green retention rate at 15 minutes.
*Enzymatic method; †Cockcroft and Gault formula; ‡Japanese equation for estimating GFR.

---

**Fig. 2.** Serum creatinine level after miriplatin administration in the three cases.
motherapy of advanced HCC. It is one of the platinum agents, although hydration after administration is not necessary of its weak renal toxicity.

Various types of resistance to therapy can occur during repetition of TACE. Platinum derivatives are frequently administered to patients with advanced HCC that is unresponsive to anthracycline and antibiotic drugs.\(^{21}\)

Miriplatin was developed as a lipophilic platinum complex in an effort to produce a superior antitumor effect in HCC with lower toxicity compared to cisplatin. Miriplatin-lipiodol suspension is a stable colloidal emulsion that is deposited within HCC tumors, where it gradually releases active derivatives of miripla-
According to pharmacokinetic studies, the plasma concentrations of total platinum in patients treated with miriplatin is much lower than that after administration in patients administered intra-arterial cisplatin: the Cmax is approximately 300-fold lower and the Tmax roughly 500-fold longer than the corresponding values for intra-arterial cisplatin. Theoretically, therefore, it can be administered even in patients of advanced HCC patients with chronic renal failure if visceral angiography can be performed.

Clinical trials have shown that miriplatin is effective for the treatment of HCC, but the safety and efficacy of miriplatin has not been evaluated in HCC patients with chronic renal failure. Herein we presented three HCC cases with stage 4 chronic renal failure who received transcatheter arterial chemotherapy with miriplatin. In all three cases, no serious adverse events were observed, and serum creatinine level did not increase, even in the patient who had experienced renal failure due to cisplatin administration (Fig. 2). Repeated injection of miriplatin appears to be also safe in HCC patients with chronic renal failure.

The present results might suggest that transcatheter arterial chemotherapy with miriplatin can be safely used in HCC patients with chronic renal failure. A prospective study is required to assess the most effective, least nephrotoxic anticancer agent among the various platinum derivatives. Miriplatin appears to be a promising agent for HCC patients with chronic renal failure.

CONFLICTS OF INTEREST

The following authors have received honoraria (lecture fee) from Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan; Hiromitsu Kumada, MD, Kenji Ikeda, MD, Yasuji Arase, MD, Yoshiyuki Suzuki, MD, Fumitaka Suzuki, MD, and Norio Akuta, MD.

REFERENCES

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Kamada K, Nakamizo T, Kitamoto M, et al. Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc Interv Radiol 2001;12:847-854.
3. Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002;224:47-54.
4. Ikeda M, Maeda S, Shihata J, et al. Transcatheter arterial chemotherapy and without embolization in patients with hepatocellular carcinoma. Oncology 2004;66:24-31.
5. Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131:461-469.
6. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30:6-25.
7. Ikeda M, Maeda S, Ashihara H, Nagahama H, Tanaka M, Sasaki Y. Transcatheter arterial infusion chemotherapy with cisplatin-lipiodol suspension in patients with hepatocellular carcinoma. J Gastroenterol 2010;45:60-67.
8. Laragh JH, Cannon PJ, Benzel CJ, Sicinski AM, Meltzer JI. Angiotensin II, Norepinephrine, and renal transport of electrolytes and water in normal man and in cirrhosis with ascites. J Clin Invest 1963;42:1179-1192.
9. Cardenas A, Ginès P, Uri J, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology 2001;34(4 Pt 1):671-676.
10. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology 2003;37:233-243.
11. Huo TI, Wu JC, Lee PC, Chang FY, Lee SD. Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. Liver Int 2004;24:210-215.
12. Huo TI, Wu JC, Huang YH, et al. Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome. Aliment Pharmacol Ther 2004;19:999-1007.
13. Hsu CY, Huang YH, Su CW, et al. Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. Liver Int 2010;30:77-84.
14. Maeda M, Uchida NA, Sasaki T. Liposoluble platinum(II) complexes with antitumor activity. Jpn J Cancer Res 1986;77:523-525.
15. Kishimoto S, Ohtani A, Fukuda H, Fukushima S, Takeuchi Y. Relation between intracellular accumulation and cytotoxic activity of cis-[(1R, 2R)-1,2-cyclohexanediamine-N, N’bis(myristato)] platinum(II) suspended in Lipiodol. Biol Pharm Bull 2003;26:683-686.
16. Fujiyama S, Shihata J, Maeda S, et al. Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodol. Br J Cancer 2003;89:1614-1619.
17. Okusaka T, Okada S, Nakaniishi T, Fujiyama S, Kubo Y. Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma. Invest New Drugs 2004;22:169-176.
18. Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of human hepatoma cells orthotopically implanted in nude rats. Cancer Sci 2009;100:189-194.
19. Hanada M, Baba A, Tsutsumishita Y, et al. Intra-hepatic arterial...
administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol 2009;64:473-483.

20. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002;39(Suppl 2):S7-S245.

21. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-992.

22. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.

23. Kawamura Y, Ikeda K, Hirakawa M, et al. Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin. Hepatol Res 2009;39:346-354.